<DOC>
	<DOCNO>NCT01461655</DOCNO>
	<brief_summary>The aim proof principle study evaluate efficacy safety sequential application two marketed product treatment acne vulgaris , use Split-Face model</brief_summary>
	<brief_title>Efficacy Tolerability Sequential Application Two Marketed Products Patients With Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Subjects understand sign informed consent form Male female subject 18 35 year ( include ) age present acne vulgaris face . A minimum 10 inflammatory lesion ( papule pustule ) entire face , minimum 20 noninflammatory lesion ( open comedo close comedo ) entire face . Disease severity grade mild moderate accord investigator 's global assessment ( grade 2 grade 3 ) Females pregnant , childbearing potential wish become pregnant study , breast feeding . Subjects acne cyst one nodule per hemiface . Subjects acne conglobata , acne fulminans , secondary acne ( e.g . chloracne , druginduced acne ) , acne require systemic treatment . Subjects dark pigmentation skin skin type may , way , confound interpretation study result ( skin type V VI Fitzpatrick scale . Subjects facial skin disorder may interfere study assessment . Subjects use medicate cosmetic and/or soap ( include soap contain antibacterial agent benzoyl peroxide , keratolytic agent salicylic acid , skin fresheners/astringents aftershave product ) face duration study . Subjects history actinic keratosis face skin cancer . Use hormonal oral contraceptive acne control le 6 month prior randomisation . Subjects use one follow systemic medication within 4 week randomisation study , could effect trial disease . systemic corticosteroid , antiacne drug , oral retinoids immunosuppressive drug . Subjects use systemic NSAIDs ( include aspirin ) within 1 week randomisation study . Subjects use paracetamol within 1 week randomisation . Paracetamol allow study maximum dose 1g twice daily maximum 3 consecutive day Subjects use one follow topical medication within 2 week randomisation study , could effect trial disease : antiinflammatory drug ( e.g . topical corticosteroid , NSAIDs ) , antiacne drug , topical retinoids , topical antibacterial agent topical immunosuppressive drug . Subjects know suspected hypersensitivity component ( ) investigational product nonsteroidal anti inflammatory drug NSAIDs ( e.g. , aspirin , diclofenac , ibuprofen , ketoprofen ) . Subjects presence clinically significant gastrointestinal pathology ( e.g . chronic diarrhea , inflammatory bowel disease ) , unresolved gastrointestinal symptom ( e.g . diarrhea , vomit ) . Subjects know presence active peptic ulcer . Subjects history ( last 10 year ) know presence asthma . Subjects history ( last 5 year ) know presence rhinitis urticaria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>